Results 61 to 70 of about 5,063 (199)

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela   +2 more
wiley   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

open access: yesAllergy, Volume 81, Issue 9, Page 3345-3360, September 2026.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton   +19 more
wiley   +1 more source

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma

open access: yesAllergy, Volume 81, Issue 9, Page 3261-3272, September 2026.
EXPEDITION (NCT02573233) assessed the effects of dupilumab on airway inflammation in patients with persistent asthma using bronchoscopy and gene expression analysis. Dupilumab showed no appreciable effect on inflammatory cell types in biopsies or BALF samples.
Michael E. Wechsler   +22 more
wiley   +1 more source

Parthenium dermatitis manifesting clinically as polymorphic light eruption and prurigo nodularis- like lesions with vasculitis-like picture on histopathology

open access: yesIndian Dermatology Online Journal, 2011
Parthenium dermatitis is a widespread and distressing dermatoses in rural and urban India caused by the air borne allergen of the Compositae weed Parthenium hysterophorus.
Chembolli Lakshmi   +3 more
doaj   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, Volume 65, Issue 9, Page 1846-1855, September 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

Prurigo nodularis in bambino con infestazione da Ascaris lumbricoides

open access: yes, 2009
La “prurigo nodularis” è una dermatosi cronica a eziopatogenesi non ben definita caratterizzata dalla presenza di noduli pruriginosi prevalenti sulla superficie estensoria degli arti.
D. Boccardi   +3 more
core   +1 more source

Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis

open access: yesMedicines, 2020
Background: Prurigo nodularis (PN) is an intensely pruritic skin condition of considerable morbidity. However, the pathogenesis of PN and its association with underlying neuropathy is unclear.
John-Douglas Matthew Hughes   +7 more
doaj   +1 more source

Update on biologic and small molecules treatments in pediatric allergic diseases

open access: yesPediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker   +10 more
wiley   +1 more source

Prurigo Nodularis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1950
W P, ELFORD, F P, WEBER
openaire   +2 more sources

Home - About - Disclaimer - Privacy